An interventional study of MetaNeb Therapy and Standard of care in Atelectases, Postoperative Pulmonary, sponsored by Shanghai Zhongshan Hospital. Completed at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Pulmonary Atelectasis with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Pulmonary Atelectasis · China.
Among the 24 studies in Pulmonary Atelectasis with a site in China, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2026, is one of 19 with no phase, and was the 19th registered.
378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.
Browse Pulmonary Atelectasis studies →13 of the 24 studies in Pulmonary Atelectasis with a site in China are open now. Recruiting first, the newest first:
Southeast University, China · Sites in China
Ages 18+
Capital Medical University · Sites in China
Ages 18+
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18+ · Women only
Tongji Hospital · Sites in China
Ages 18–80
Shanghai Zhongshan Hospital · Sites in China
Ages 20–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 5 started in 2026.
This study's enrollment of 178 is above the median of 60 across 268 interventional studies indexed under Pulmonary Atelectasis.
Median enrollment 90 across the 21 interventional studies, 80 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 24 has an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Shanghai Zhongshan Hospital has 4 studies filed under Pulmonary Atelectasis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pulmonary Atelectasis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239557Sixth Affiliated Hospital, Sun Yat-sen UniversityOptimal Interval for Periodic Alveolar Recruitment Maneuvers Achieving 90% Lung Re-expansion During Intraoperative Ventilation | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Pulmonary Atelectasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether the MetaNeb® System can effectively prevent and treat early postoperative atelectasis in adult patients admitted to ICU after esophagectomy for esophageal cancer.
The main question it aims to answer is: can the MetaNeb® system significantly reduce the lung ultrasound score (LUSS) indicating atelectasis on postoperative days 1 and 2? Participants will be randomly assigned to either the standard treatment or MetaNeb group, undergo lung ultrasound and electrical impedance tomography (EIT) assessments on postoperative days 1 and 2, receive at least 4 sessions of MetaNeb therapy on postoperative day 1 if in the intervention group, be monitored for oxygenation indices, ICU stay duration, incidence of mechanical ventilation, need for bronchoscopic intervention, and adverse events like pneumothorax.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Standard of care
Device: MetaNeb Therapy
Patients in the MetaNeb group receive at least 4 sessions of MetaNeb therapy on postoperative day 1 (each session includes cycles of CPEP and CHFO modes totaling 10 minutes).
Standard postoperative care, including guidance on coughing and expectoration, turning and back percussion, and early mobilization (getting out of bed for physical activity).
The difference of lung ultrasound scores (LUSS) indicating atelectasis on postoperative day 1 and 2
Time frame: From postoperative day 1 to day 2
The difference of dorsal ventilation region assessed by electrical impedance tomography (EIT) on postoperative day 1 and 2
Time frame: From postoperative day 1 to day 2
The difference of PaO2/FiO2 ratios on postoperative day 1 and 2
Time frame: From postoperative day 1 to day 2
The number of cases that underwent bronchoscopy intervention during ICU stay
Time frame: From admission to ICU discharge
The number of cases that underwent high flow oxygen therapy or mechanical ventilation
Time frame: From admission to ICU discharge
Length of ICU stay
Time frame: From admission to ICU discharge
The number of cases that develop pneumothorax during intervention
Time frame: From admission to the end of intervention at postoperative day 2
Clinical Pulmonary Infection Score
Clinical Pulmonary Infection Score
Time frame: From postoperative day 1 to day 2
Plan to share: Undecided — It might compromise the interests of MetNeb company and we still need to negotiate it further.
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Apr 2026, 3 months.
Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's 3 months is below that.
Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → May 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.